S. Hadziyannis

K. Reddy, S. Zeuzem, M. Shiffman, 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies

P. Marcellin, K. Reddy, M. Diago, 2012, Expert opinion on drug safety.

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action.

J. Bruix, G. Gerken, M. Colombo, 1998, Journal of hepatology.

Primary liver cancer and its relationship to chronic infection with the hepatitis B virus

S. Hadziyannis, 1981, Springer Seminars in Immunopathology.

Expression of HBsAg and HBcAg in liver tissue: correlation with disease activity.

K. Stefanaki, L. Nakopoulou, S. Hadziyannis, 1992, Histology and histopathology.

Unrevealing the natural course of the so-called “inactive HBsAg or HBV carrier state”

S. Hadziyannis, 2007, Hepatology international.

Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others).

S. Hadziyannis, G. Papatheodoridis, 2003, Journal of hepatology.

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α‐2a plus ribavirin

P. Marcellin, J. Rakela, S. Govindarajan, 2007, Journal of viral hepatitis.

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin

O. Weiland, G. Foster, M. Fried, 2007, Scandinavian journal of gastroenterology.

Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B.

W. Carman, A. Owsianka, S. Dourakis, 1998, Journal of hepatology.

Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa‐2b for 6 or 12 months: A 4‐year follow‐up of 211 patients

J. Koskinas, S. Hadziyannis, G. Kafiri, 1997, Hepatology.

Hepatitis C virus 1b is the dominant genotype in HCV‐related carcinogenesis: A case‐control study

D. Trichopoulos, A. Hatzakis, G. Karvountzis, 1996, International journal of cancer.

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.

S. Hadziyannis, G. Papatheodoridis, E. Manesis, 2001, Journal of hepatology.

The spectrum of extrahepatic manifestations in hepatitis C virus infection

S. Hadziyannis, 1997, Journal of viral hepatitis.

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B

P. Marcellin, C. Yurdaydın, G. Lau, 2009, Hepatology.

Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial

S. Hadziyannis, E. Hadziyannis, G. Papatheodoridis, 2002, American Journal of Gastroenterology.

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

P. Marcellin, P. Ferenci, D. Messinger, 2012, Journal of hepatology.

Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α‐2a (40KD) plus ribavirin

T. Berg, P. Marcellin, S. Zeuzem, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Core Protein Evolution After Selection of Hepatitis B Precore Mutants and Correlation with Disease Severity

H. Thomas, G. Fattovich, A. Alberti, 1994 .

Diabetes mellitus and chronic hepatitis C virus infection

S. Hadziyannis, B. Karamanos, 1999, Hepatology.

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis

S. Hadziyannis, G. Papatheodoridis, V. Papadimitropoulos, 2001, Alimentary pharmacology & therapeutics.

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

Mahmoud A. Khattab, M. Manns, M. Colombo, 2011, Journal of hepatology.

Nonhepatic manifestations and combined diseases in HCV infection

S. Hadziyannis, 1996, Digestive Diseases and Sciences.

Skin diseases associated with hepatitis C virus infection

S. Hadziyannis, 1998, Journal of the European Academy of Dermatology and Venereology : JEADV.

Controlling hepatitis C

D. Vassilopoulos, S. Hadziyannis, 2001 .

Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients.

D. Samuel, H. Bismuth, J. Benhamou, 1990, Journal of hepatology.

Immune thrombocytopenia and α-interferon therapy

S. Hadziyannis, M. Deutsch, S. Dourakis, 1996 .

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

S. Zeuzem, M. Shiffman, M. Fried, 2011, Journal of hepatology.

Update on Hepatitis B Virus Infection: Focus on Treatment

S. Hadziyannis, 2014, Journal of clinical and translational hepatology.

Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature.

S. Hadziyannis, A. Alexopoulou, S. Dourakis, 2004, European journal of internal medicine.

Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin

M. Fried, D. Messinger, D. Jensen, 2008, The American Journal of Gastroenterology.

EDITORIAL: Decreasing prevalence of hepatitis D virus infection

S. Hadziyannis, 1997 .

Recombinant interferon‐α therapy for acute hepatitis B: a randomized, double‐blind, placebo‐controlled trial

M. Koutelou, S. Hadziyannis, N. Tassopoulos, 1997, Journal of viral hepatitis.

Lymphoblastoid interferon in controlled trials of chronic hepatitis B virus infection

S. Hadziyannis, 1988, Hepatology.

Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B

S. Hadziyannis, E. Hadziyannis, 2020, Expert review of gastroenterology & hepatology.

Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

Y. Liaw, S. Hadziyannis, M.‐L. Chang, 2015, Alimentary pharmacology & therapeutics.

Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B

S. Hadziyannis, 2012, Alimentary pharmacology & therapeutics.

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients

P. Marcellin, C. Yurdaydın, M. Brunetto, 2012, Hepatology International.

Milestones and perspectives in viral hepatitis B

S. Hadziyannis, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Combination of interferon α therapy with non-steroidal anti-inflammatory drugs in chronic hepatitis C

S. Hadziyannis, 2000 .

Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs.

E. Cholongitas, D. Vassilopoulos, A. Mentis, 2004, The American journal of medicine.

Optic tract neuropathy complicating low-dose interferon treatment.

S. Hadziyannis, D. Brouzas, E. Manesis, 1994, Journal of hepatology.

Neurovisual impairment: A frequent complication of alpha‐interferon treatment in chronic viral hepatitis

S. Hadziyannis, D. Brouzas, M. Moschos, 1998, Hepatology.

Absence of the negative strand of GBV-C/HGV RNA from the liver

S. Hadziyannis, G. Zacharakis, A. Laras, 1999 .

Expression of immunoreactive forms of the hepatitis C NS5A protein in E. coli and their use for diagnostic assays

V. Miriagou, S. Hadziyannis, U. Georgopoulou, 2002, Archives of Virology.

Complement Levels in Relation to Certain Antibodies in Polytransfused Thalassaemic Patients 1

S. Hadziyannis, J. Economidou, M. Constantoulakis, 1976, Vox sanguinis.

Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience.

Anastasia C. Thanopoulou, J. Koskinas, S. Hadziyannis, 2002, European journal of internal medicine.

Peginterferon-α2a (40 kDa) for chronic hepatitis C

S. Hadziyannis, G. Papatheodoridis, 2003, Expert opinion on pharmacotherapy.

Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B virus infection in comparison to other markers of active virus replication.

J. Sninsky, G. Raimondo, D. Shafritz, 1987, Journal of hepatology.

Autoimmune hepatitis associated with the antiphospholipid syndrome.

S. Hadziyannis, I. Papanikolaou, S. Dourakis, 2001, European journal of gastroenterology & hepatology.

Treatment of special populations with chronic hepatitis B infection

S. Hadziyannis, I. Rapti, 2011, Expert review of gastroenterology & hepatology.

Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens.

D. Shafritz, M. Kew, D. Shouval, 1981, The New England journal of medicine.

Liver and biliary Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection

S. Hadziyannis, P. Karayiannis, L. Montano, 2006 .

Pre‐S1 and pre‐S2 gene‐encoded proteins in liver and serum in chronic hepatitis delta infection

S. Hadziyannis, U. Georgopoulou, E. Psalidaki, 1991, Journal of medical virology.

Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma.

R. Burk, H. Will, G. Raimondo, 1988, Virology.

Liver disease activity and hepatitis B virus replication in chronic delta antigen‐positive hepatitis B virus carriers

M. Sherman, D. Shafritz, S. Hadziyannis, 1985, Hepatology.

Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection.

A. Lok, H. Thomas, S. Hadziyannis, 1984, Gut.

Endemic hepatitis delta virus infection in a Greek community.

A. Hatzakis, S. Hadziyannis, C. Papaioannou, 1987, Progress in clinical and biological research.

Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature

M. Manns, H. Thomas, S. Sauleda, 2000 .

Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research.

M. Manns, H. Thomas, S. Sauleda, 2000, European journal of gastroenterology & hepatology.

Use of alpha-interferon in the treatment of chronic delta hepatitis.

S. Hadziyannis, 1991, Journal of hepatology.

Letter: safe and effective cessation of long‐term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg‐negative chronic hepatitis B

S. Hadziyannis, 2015, Alimentary pharmacology & therapeutics.

Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?

D. Vassilopoulos, S. Hadziyannis, V. Sevastianos, 2014, Current Hepatology Reports.

What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B

D. Vassilopoulos, S. Hadziyannis, 2012, Current Hepatitis Reports.

18 OUTCOME OF HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHB) 5 YEARS AFTER DISCONTINUATION OF LONG TERM ADEFOVIR DIPIVOXIL (ADV) TREATMENT

S. Hadziyannis, V. Sevastianos, I. Rapti, 2009 .

80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

M. Sherman, C. Yurdaydın, R. Hindes, 2006 .

Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B

P. Marcellin, J. Ma, Z. Goodman, 2005 .

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

C. Gibbs, P. Marcellin, R. Gish, 2003, Gastroenterology.

Why and how to treat chronic hepatitis C.

S. Hadziyannis, 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

New developments in the treatment of chronic hepatitis B

S. Hadziyannis, 2006, Expert opinion on biological therapy.

Serum HBV-DNA levels in inactive hepatitis B virus carriers.

S. Hadziyannis, G. Papatheodoridis, E. Manesis, 2002, Gastroenterology.

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.

J. Hulot, H. Izzedine, G. Deray, 2004, Kidney international.

57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy

C. Gibbs, V. Thibault, S. Arterburn, 2004 .

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.

M. Fried, S. Hadziyannis, 2004, Seminars in liver disease.

Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection

S. Hadziyannis, G. Papatheodoridis, 2004, Expert review of anti-infective therapy.

[53] VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBeAg-NEGATIVE CHB TREATED WITH PEGINTERFERON a-2a (40 kD) ± LAMIVUDINE: 3-YEAR FOLLOW-UP RESULTS

P. Marcellin, C. Yurdaydın, P. Farci, 2007 .

Combination of interferon alpha therapy with non-steroidal anti-inflammatory drugs in chronic hepatitis C.

S. Hadziyannis, 2000, Gut.

Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis

H. Thomas, Roger Williams, W. Carman, 1991, Hepatology.

REVIEW: Hepatitis delta

S. Hadziyannis, 1997, Journal of gastroenterology and hepatology.

Erratum: impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action (Journal of Hepatology (1998) 29 (173-83))

J. Bruix, G. Gerken, M. Colombo, 1998 .

Chronic viral hepatitis.

S. Hadziyannis, 1974, Clinics in gastroenterology.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

P. Marcellin, V. Balan, S. Zeuzem, 2004, Annals of internal medicine.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

George Kitis, Katyna Borroto-Esoda, P. Marcellin, 2006, Gastroenterology.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

M. Wulfsohn, P. Marcellin, Z. Goodman, 2003, The New England journal of medicine.

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

E. Schiff, B. Bacon, R. Gish, 2005, Gastroenterology.

Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis.

J. Koskinas, S. Hadziyannis, Z. Manika, 1999, European journal of gastroenterology & hepatology.

In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter.

J. Koskinas, S. Hadziyannis, A. Laras, 2002, Virology.

The precore sequence of hepatitis B virus is required for nuclear localization of the core protein

S. Hadziyannis, P. Karayiannis, M. McGarvey, 1997, Hepatology.

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action

J. Bruix, Roger Williams, M. Colombo, 1998 .

Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels

Olga Angelopoulou, S. Hadziyannis, E. Hadziyannis, 2007, Antiviral therapy.

A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen‐negative chronic hepatitis B

S. Hadziyannis, E. Manesis, G. Papatheodoridis, 2006, Alimentary pharmacology & therapeutics.

Hepatitis B e antigen–negative chronic hepatitis B

D. Vassilopoulos, S. Hadziyannis, 2001, Hepatology.

Diagnosis and management of pre‐core mutant chronic hepatitis B

S. Hadziyannis, G. Papatheodoridis, G. Papatheodoridis, 2001, Journal of viral hepatitis.

Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

S. Hadziyannis, E. Manesis, 2001 .

The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B

S. Hadziyannis, G. Papatheodoridis, E. Manesis, 2001 .

Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B

S. Hadziyannis, G. Papatheodoridis, E. Dimou, 2000, Hepatology.

Serum β2 microglobulin in malignant lymphoproliferative disorders

G. Karvountzis, S. Hadziyannis, Z. Komninos, 1985 .

Telbivudine in the treatment of chronic hepatitis B

D. Vassilopoulos, S. Hadziyannis, 2008, Expert review of gastroenterology & hepatology.

Emerging treatments in chronic hepatitis B

S. Hadziyannis, G. Papatheodoridis, 2004, Expert opinion on emerging drugs.

241 Long-term (96 weeks) adefovir dipivoxil in HBEAG negative chronic hepatitis results in significant virological, biochemical and histological improvement

M. Wulfsohn, P. Marcellin, S. Lim, 2003 .

1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B

P. Marcellin, C. Yurdaydın, G. Lau, 2003 .

Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.

E. Schiff, Ting Chang, R. Hindes, 2002 .

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

P. Marcellin, C. Yurdaydın, G. Lau, 2004, The New England journal of medicine.

Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

S. Hadziyannis, G. Papatheodoridis, Stephanos Hadziyannis1, 2006, Seminars in liver disease.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Graeme Currie, George Kitis, P. Marcellin, 2005, The New England journal of medicine.

The natural course of chronic hepatitis B virus infection and its management.

D. Vassilopoulos, S. Hadziyannis, E. Hadziyannis, 2013, Advances in pharmacology.

Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results

E. Schiff, J. Villeneuve, D. Samuel, 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Treatment of HBeAg-Negative Chronic Hepatitis B with Nucleoside/Nucleotide Analogs

S. Hadziyannis, 2004 .

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil

C. Gibbs, P. Marcellin, R. Gish, 2003 .

Assessment of Depression in Patients with Chronic Viral Hepatitis: Effect of Interferon Treatment

J. Koskinas, S. Hadziyannis, E. Manesis, 2003, Digestive Diseases.

Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease

S. Hadziyannis, G. Papatheodoridis, E. Dimou, 2002, Hepatology.

Current management of chronic hepatitis B

S. Hadziyannis, G. Papatheodoridis, 2004, Alimentary pharmacology & therapeutics.

Famciclovir treatment of anti-HBE+ chronic hepatitis B: Results of a randomized, placebo-controlled study

C. Trépo, F. Bonino, R. Saltzman, 2000 .

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

S. Hadziyannis, E. Manesis, 2001, Gastroenterology.

Chronic hepatitis B: a critical appraisal of current approaches to therapy.

M. Buti, E. Schiff, E. Keeffe, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Treatment options for chronic hepatitis B not responding to interferon.

S. Hadziyannis, 2003, Journal of hepatology.

GS-98-438 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results

M. Wulfsohn, P. Marcellin, S. Lim, 2002 .

Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B

P. Marcellin, M. Tong, S. Arterburn, 2007, Alimentary pharmacology & therapeutics.

The role of entecavir in the treatment of chronic hepatitis B

S. Hadziyannis, E. Dimou, V. Papadimitropoulos, 2007, Therapeutics and clinical risk management.

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

P. Marcellin, C. Yurdaydın, M. Brunetto, 2013, Journal of hepatology.

Natural history of chronic hepatitis B in Euro-Mediterranean and African countries.

S. Hadziyannis, 2011, Journal of hepatology.

The Natural History of Chronic HBV Infection and Geographical Differences

Y. Liaw, M. Brunetto, S. Hadziyannis, 2010, Antiviral therapy.

Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine

George Kitis, G. Kitis, S. Hadziyannis, 2005, Hepatology.

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Jörg Petersen, Darius Moradpour, Jean-Michel Pawlotsky, 2009, Journal of hepatology.

Treatment of HBeAg-negative chronic hepatitis B.

D. Vassilopoulos, S. Hadziyannis, G. Papatheodoridis, 2003, Seminars in liver disease.

46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES)

P. Marcellin, S. Lim, M. Rizzetto, 2004 .

Review article: current management of chronic hepatitis B.

S. Hadziyannis, G. Papatheodoridis, 2004, Alimentary pharmacology & therapeutics.

95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

P. Marcellin, G. Lau, P. Farci, 2004 .

Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen–negative chronic hepatitis B virus infection

E. Cholongitas, S. Hadziyannis, G. Papatheodoridis, 2003, American Journal of Gastroenterology.

Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B

M. Wulfsohn, P. Marcellin, S. Lim, 2003 .

Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy.

S. Hadziyannis, 2002, Journal of hepatology.

Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti‐HBe Positive Carriers of Hepatitis B Virus

D. Shafritz, S. Hadziyannis, D A Shafritz, 2007, Hepatology.

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

P. Marcellin, C. Yurdaydın, G. Lau, 2009, Gastroenterology.

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B.

A. Makris, S. Hadziyannis, C. Papaioannou, 1990, Journal of hepatology.

436 Models to predict inflammation and fibrosis in patients with chronic hepatitis B

A. Lok, P. Marcellin, Z. Goodman, 2004 .

Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study.

S. Hadziyannis, E. Manesis, A. Papakonstantinou, 1999, Journal of hepatology.

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients

J. Koskinas, S. Hadziyannis, E. Dimou, 2006, Hepatology.

P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy

P. Marcellin, Z. Goodman, S. Lim, 2006 .

Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.

S. Hadziyannis, I. Rapti, 2015, World journal of hepatology.

Hepatitis B e antigen negative chronic active hepatitis: hepatitis B virus core mutations occur predominantly in known antigenic determinants

H. Thomas, G. Fattovich, A. Alberti, 1995, Journal of viral hepatitis.

Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type B

E. Christensen, G. Fattovich, G. Realdi, 1995, Hepatology.

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

G. Fattovich, G. Realdi, G. Giustina, 1998, American Journal of Gastroenterology.

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

P. Marcellin, C. Yurdaydın, G. Lau, 2006, Gut.

683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY

P. Marcellin, C. Yurdaydın, G. Lau, 2008 .

428 Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy

E. Schiff, R. Gish, M. Rizzetto, 2004 .

Other clinical studyOccurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B

E. Christensen, G. Fattovich, G. Realdi, 1995 .

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study

E. Christensen, G. Fattovich, G. Realdi, 1994 .

483 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients

J. Pawlotsky, S. Chuck, K. Borroto-Esoda, 2006 .

75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS

M. Buti, M. Sherman, S. Strasser, 2008 .

Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission.

G. Fattovich, M. Thursz, W. Carman, 1997, The Journal of infectious diseases.

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy

P. Marcellin, K. Reddy, P. Ferenci, 2006, Hepatology.

Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C

P. Marcellin, V. Balan, S. Zeuzem, 2004, Annals of Internal Medicine.

Old and emerging therapies in chronic hepatitis C: an update

S. Hadziyannis, M. Deutsch, 2007, Journal of viral hepatitis.

2 Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation

E. Schiff, J. Villeneuve, D. Samuel, 2006 .

Measurement of hepatitis B viral DNA in serum by solution hybridization and comparison with the dot-blot hybridization technique.

A. Makris, S. Hadziyannis, L. Zignego, 1991, Hepato-Gastroenterology.

[8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE?

P. Marcellin, S. Zeuzem, M. Diago, 2007 .

Complex management issues: management of HCV in the atypical patient.

D. Vassilopoulos, S. Hadziyannis, Dimitrios Vassilopoulos, 2000, Bailliere's best practice & research. Clinical gastroenterology.

Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose

P. Marcellin, G. Ramadori, M. Diago, 2002 .

Fulminant hepatitis and the new G/GBV‐C flavivirus

S. Hadziyannis, 1998, Journal of viral hepatitis.

Pre-S2 and its antibody in fulminant type B hepatitis.

A. Budkowska, S. Hadziyannis, N. Tassopoulos, 1989, JAMA.

Quantitative HBsAg titer as predictor of response to therapy

D. Vassilopoulos, S. Hadziyannis, E. Hadziyannis, 2009 .

Clinical significance of quantitative anti-HBc IgM assay in acute and chronic HBV infection.

A. Horsch, S. Dourakis, S. Hadziyannis, 1993, Hepato-gastroenterology.

1159 Lack of ethnic differences in response to adefovir dipivoxil therapy in HBEAG+ and HBEAG- patients with chronic hepatitis B

P. Marcellin, S. Lim, Ting Chang, 2003 .

Deep jaundice in an adolescent

S. Hadziyannis, V. Sevastianos, M. Deutsch, 2003, Postgraduate medical journal.

Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection.

D. Vassilopoulos, S. Hadziyannis, 2001, Antiviral research.

Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B

S. Hadziyannis, E. Hadziyannis, G. Papatheodoridis, 2022, Virology journal.

Emergence of the long form of hepatitis delta virus antigen in transfected cells after intrahepatic transfection and during natural infection.

H. Thomas, S. Hadziyannis, P. Karayiannis, 1993, Progress in clinical and biological research.

Intracellular distribution of hepatitis B virus core protein expressed in vitro depends on the sequence of the isolate and the serologic pattern.

G. Fattovich, W. Carman, S. Hadziyannis, 2004, The Journal of infectious diseases.

Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species.

S. Hadziyannis, P. Karayiannis, H. Thomas, 1997, Journal of hepatology.

DISTRIBUTION OF IN VITRO EXPRESSED HBV CORE PROTEIN FROM ISOLATES IS DEPENDENT UPON SEQUENCE AND CORRELATES WITH DISEASE PATTERN

G. Fattovich, S. Hadziyannis, E. Dornan, 2004 .

Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg‐negative chronic hepatitis B

S. Hadziyannis, 2012, Alimentary pharmacology & therapeutics.

Current treatment options for HBV infection

D. Vassilopoulos, S. Hadziyannis, 2009 .

Molecular Cloning and Disease Association of Hepatitis G Virus: A Transfusion-Transmissible Agent

H. Margolis, M. Alter, J. Lifson, 1996, Science.

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).

E. Christensen, J. Sánchez-Tapias, G. Fattovich, 1994, Journal of hepatology.

Immune thrombocytopenia and alpha-interferon therapy.

S. Hadziyannis, M. Deutsch, S. Dourakis, 1996, Journal of hepatology.

Title Predicting response to peginterferon α2 a , lamivudine and thetwo combined for HBeAg-negative chronic hepatitis B

C. Yurdaydın, P. Farci, P. Mccloud, 2007 .

CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

P. Marcellin, Z. Goodman, S. Lim, 2006 .

Use of α-interferon in the treatment of chronic delta hepatitis

S. Hadziyannis, 1991 .

O.047 Treatment paradigms in hepatitis B e antigen negative (HBeAg-negative) chronic hepatitis B patients

S. Hadziyannis, 2006 .

Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

P. Marcellin, M. Shiffman, E. Gane, 2010, Hepatology.

Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma.

D. Trichopoulos, S. Dourakis, S. Hadziyannis, 1993, Journal of hepatology.

CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

P. Marcellin, C. Yurdaydın, G. Lau, 2009 .

Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece

J. Koskinas, S. Hadziyannis, C. Sinani, 2005, Journal of viral hepatitis.

Recent peginterferon and ribavirin combination trials

S. Hadziyannis, G. Papatheodoridis, 2004 .

Fertility and Sex Ratio of Offspring of Female HBsAg Carriers

D. Koutras, J. Hesser, S. Hadziyannis, 1979, Journal of the Royal Society of Medicine.

Hepatocellular carcinoma and type B hepatitis.

S. Hadziyannis, 1980, Clinics in gastroenterology.

Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis

E. Cholongitas, S. Hadziyannis, G. Papatheodoridis, 2003, Gut.

Differences in epidemiology, liver disease and treatment response among HCV genotypes.

J. Koskinas, S. Hadziyannis, 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatitis G virus infection: clinical characteristics and response to interferon

M. Piatak, J. Kim, S. Hadziyannis, 1997, Journal of viral hepatitis.

High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma.

G. Orfanoudakis, D. Vassilopoulos, J. Koskinas, 2011, The Journal of general virology.

Hepatitis G virus or hepatitis GB virus type C infection in thalassemic patients

C. Kattamis, S. Hadziyannis, E. Spanou, 1999, Transfusion.

Post-Infantile Giant Cell Hepatitis Associated with Autoimmune Hepatitis and Polyarteritis Nodosa

J. Koskinas, S. Hadziyannis, G. Kafiri, 2002, Scandinavian journal of gastroenterology.

Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations

J. Koskinas, S. Hadziyannis, I. Raptis, 2003, Journal of viral hepatitis.

Successful management of postoperative chylous ascites with a peritoneojugular shunt.

S. Hadziyannis, D. Voros, 1995, Journal of hepatology.

Peginterferon alfa‐2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub‐sets of older and younger HCV genotype 1 patients

K. Reddy, D. Messinger, S. Hadziyannis, 2009, Journal of viral hepatitis.

Induction interferon therapy in naïve patients with chronic hepatitis C: increased end‐of‐treatment virological responses but absence of long‐term benefit

S. Hadziyannis, E. Manesis, C. Papaioannou, 2001, Alimentary pharmacology & therapeutics.

Could HGV infection be implicated in lymphomagenesis?

C. Ferri, A. Zignego, S. Hadziyannis, 1997, British journal of haematology.

Nonalcoholic fatty liver disease: from clinical recognition to treatment

S. Hadziyannis, V. Sevastianos, 2008, Expert review of gastroenterology & hepatology.

Hepatic expression of the proliferative marker Ki‐67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma

K. Petraki, J. Koskinas, S. Hadziyannis, 2005, Journal of viral hepatitis.

Serum beta 2 microglobulin in malignant lymphoproliferative disorders.

G. Karvountzis, S. Hadziyannis, Z. Komninos, 1985, Cancer.

Decreasing prevalence of hepatitis D virus infection.

S. Hadziyannis, 1997, Journal of gastroenterology and hepatology.

Does delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma?

G. Dusheiko, M. Kew, S. Hadziyannis, 1984, British medical journal.

Fulminant hepatitis after flutamide treatment.

S. Hadziyannis, A. Alexopoulou, S. Dourakis, 1994, Journal of hepatology.

Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease.

S. Hadziyannis, G. Kafiri, M. Deutsch, 1999, European journal of gastroenterology & hepatology.

Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial

S. Hadziyannis, E. Manesis, G. Giannoulis, 1995, Hepatology.

Hepatocellular carcinoma after treatment cessation in non‐cirrhotic HBeAg‐negative chronic hepatitis B: A multicentre cohort study

J. Kao, Chun-Jen Liu, T. Su, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Ursodeoxycholic-acid for primary biliary cirrhosis: Final results of A12-year prospective, randomised, controlled trial

S. Hadziyannis, E. Hadziyannis, G. Papatheodoridis, 2000 .

Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis

S. Hadziyannis, G. Papatheodoridis, M. Deutsch, 2008, European journal of gastroenterology & hepatology.

Combined hepatocellular-cholangiocarcinoma presented with massive pulmonary embolism.

J. Koskinas, S. Hadziyannis, G. Kafiri, 2000, Hepato-gastroenterology.

Commentary: efficacy and safety of ribavirin plus pegylated interferon‐alpha in geriatric patients with chronic hepatitis C

S. Hadziyannis, V. Sevastianos, 2013, Alimentary pharmacology & therapeutics.

Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma.

S. Hadziyannis, M. Deutsch, S. Dourakis, 1997, European journal of gastroenterology & hepatology.

Changing epidemiology and spreading modalities of hepatitis delta virus infection in Greece.

S. Dourakis, S. Hadziyannis, E. Hadziyannis, 1993, Progress in clinical and biological research.

Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population

A. Goulas, G. Germanidis, J. Koskinas, 2016, Pharmacological reports : PR.

Glucose intolerance in chronic hepatitis C and B: risk factors and prevalence in general population

S. Hadziyannis, E. Manesis, E. Siakavellas, 2002 .

[792] IMPACT OF ADEFOVIR DIPIVOXIL ON LIVER FIBROSIS AND ACTIVITY ASSESSED WITH FIBROTEST-ACTITEST IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION

P. Marcellin, Y. Ngo, Z. Goodman, 2007 .

Splenomegaly in asymptomatic chronic carriers of hepatitis B and D viruses

S. Hadziyannis, E. Manesis, S. Georgiou, 1994 .

Clinical Features of Hepatitis Delta Virus

D. Vassilopoulos, S. Hadziyannis, 2006 .

Safety of peginterferon alfa‐2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

P. Ferenci, E. Gane, G. Dusheiko, 2012, Liver international : official journal of the International Association for the Study of the Liver.

A. Hatzakis, S. Hadziyannis, 1984, American journal of epidemiology.

Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus.

P. Klenerman, P. Borrow, M. Lucas, 2003, The Journal of general virology.

Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B

Y. Liaw, S. Hadziyannis, 2014, Gut.

Chronic hepatitis B.

H. Thomas, S. Hadziyannis, S. Schalm, 1990, Progress in liver diseases.

Effect of antiviral therapy on the immunohistochemical expression of bcl‐xL and bax protein in patients with HBeAg‐negative chronic hepatitis B

E. Cholongitas, D. Tiniakos, S. Hadziyannis, 2011, Journal of medical virology.

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen.

S. Hadziyannis, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION

H. Thomas, W. Carman, S. Hadziyannis, 1989, The Lancet.

Efficacy of long term lamivudine therapy in HBeAg negative chronic hepatitis B

S. Hadziyannis, G. Papatheodoridis, E. Dimou, 2000 .

Splenic infarct as a late complication of liver transplantation.

S. Hadziyannis, A. Alexopoulou, S. Dourakis, 1998, European journal of gastroenterology & hepatology.

Ileoileocecal intussusception in an adult caused by a lipoma of the terminal ileum

S. Hadziyannis, I. Papanikolaou, S. Dourakis, 2007 .

Hashimoto Encephalopathy with Pegylated Interferon Alfa-2b and Ribavirin

D. Vassilopoulos, G. Tolis, J. Koskinas, 2005, The Annals of pharmacotherapy.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

P. Marcellin, C. Yurdaydın, G. Lau, 2004, The New England journal of medicine.